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Hyperbilirubinaemia is a ubiquitous transitional morbidity in the vast majority of newborns and a leading cause of
hospitalisation in the first week of life worldwide. While timely and effective phototherapy and exchange transfusion are
well proven treatments for severe neonatal hyperbilirubinaemia, inappropriate or ineffective treatment of
hyperbilirubinaemia, at secondary and tertiary hospitals, still prevails in many poorly-resourced countries accounting for a
disproportionately high burden of bilirubin-induced mortality and long-term morbidity. As part of the efforts to curtail the
widely reported risks of frequent but avoidable bilirubin-induced neurologic dysfunction (acute bilirubin encephalopathy
(ABE) and kernicterus) in low and middle-income countries (LMICs) with significant resource constraints, this article
presents a practical framework for the management of late-preterm and term infants (≥35 weeks of gestation)
with clinically significant hyperbilirubinaemia in these countries particularly where local practice guidelines are
lacking. Standard and validated protocols were followed in adapting available evidence-based national guidelines
on the management of hyperbilirubinaemia through a collaboration among clinicians and experts on newborn
jaundice from different world regions. Tasks and resources required for the comprehensive management of infants
with or at risk of severe hyperbilirubinaemia at all levels of healthcare delivery are proposed, covering primary prevention,
early detection, diagnosis, monitoring, treatment, and follow-up. Additionally, actionable treatment or referral levels for
phototherapy and exchange transfusion are proposed within the context of several confounding factors such as
widespread exclusive breastfeeding, infections, blood group incompatibilities and G6PD deficiency, which place
infants at high risk of severe hyperbilirubinaemia and bilirubin-induced neurologic dysfunction in LMICs, as well
as the limited facilities for clinical investigations and inconsistent functionality of available phototherapy devices. The
need to adjust these levels as appropriate depending on the available facilities in each clinical setting and the risk
profile of the infant is emphasised with a view to avoiding over-treatment or under-treatment. These recommendations
should serve as a valuable reference material for health workers, guide the development of contextually-relevant
national guidelines in each LMIC, as well as facilitate effective advocacy and mobilisation of requisite resources for the
optimal care of infants with hyperbilirubinaemia at all levels.
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Neonatal hyperbilirubinaemia is a leading cause of hos-
pital admission/re-hospitalisation in the first week of life
globally [1-3]. Timely and appropriate treatment with
phototherapy and/or exchange transfusion are effective
in controlling excessive bilirubin levels in the affected in-
fants [4,5]. Otherwise, severe hyperbilirubinaemia may
progress to acute bilirubin encephalopathy (ABE) or ker-
nicterus with a significant risk of mortality in newborns
[6-8]. Survivors may also acquire long-term neurodeve-
lopmental sequelae such as cerebral palsy, sensorineural
hearing loss, intellectual difficulties or gross develop-
mental delays [9-13]. It is estimated that, worldwide, se-
vere hyperbilirubinaemia affects at least 481,000 term or
near-term newborn babies annually, of whom 114,000
die and more than 63,000 survive with moderate or se-
vere disability [14,15]. At least, 75% of the affected in-
fants reside in sub-Saharan Africa and South Asia [14].
In low- and middle-income countries (LMICs), delay
in seeking care for infants with hyperbilirubinaemia as
well as delay in providing appropriate treatment when
affected infants present in health facilities is commonly
reported [16,17]. Where phototherapy devices are avail-
able, if at all, lack of relevant guidelines or inadequate
knowledge of essential requirements for effective treat-
ment results in frequent and potentially avoidable ex-
change transfusions [18-21]. We, therefore, set out to
identify key considerations for the effective management
of late-preterm and term infants (≥35 weeks of gesta-
tion) with significant hyperbilirubinaemia presenting at
health facilities in LMICs.
Review
Methodology
Guidelines for the management of hyperbilirubinaemia in
high-income countries are unlikely to address the peculiar
challenges in LMICs without appropriate modification
[17,22,23]. Adaptation of existing evidence-based guide-
lines from one geographical, economic and socio-cultural
context to another is an internationally accepted alterna-
tive to the more costly, time-consuming, de novo guideline
development for improved health care delivery [24]. In
this report, we followed relevant protocols of the WHO
Handbook for Guideline Development [25], ADAPTE
Guideline Adaptation Toolkit [26], and AGREE II-Global
Rating Scale [27], for the adaptation of clinical practice
guidelines. Based on prior in-depth reviews of the litera-
ture from 1970 to 2013 on the burden of neonatal hyper-
bilirubinaemia and current management practices in
LMICs [17,22], we identified four major themes for im-
proving the care of affected infants namely: primary pre-
vention, early detection and monitoring, treatment and
follow-up. We then undertook a review of existing guide-
lines (see Additional file 1: Table S1) and relevantliterature from both high-income and LMICs to identify
key issues relevant to improved care at primary, secondary
and tertiary levels in LMICs [28,29]. The existing guide-
lines were rated individually by the core working group
(CWG) and one external content methodologist who had
no prior involvement with generating these guidelines.
The overall average score for each guideline was com-
puted based on the seven components of the AGREE-II
instrument: methodology, presentation, completeness, ap-
propriateness, overall quality, disposition for personal use
and likelihood of recommending the guideline to others
[27]. We developed a practice framework for different
levels of newborn care based on essential tools and skills
considered appropriate for each level of care. The pro-
posals aimed at balancing the safe, effective, patient-
centred, timely, efficient and equitable components of
quality care enunciated by the Institute of Medicine [30],
as well as minimising the risk of unintended harms such
as costly, unnecessary overtreatment or increased parental
anxiety. Where scientific evidence was lacking or limited,
proposed actions were based on consensus among the
CWG using the Delphi process [31]. The draft and final
proposals were critically reviewed by an international
panel of experts for scientific soundness and practicality.
The experts were identified and agreed by the CWG
based on their independently verifiable work on the
subject-matter and with a view to achieving a fair rep-
resentation from all world regions. While the expert
panel review was not intended as individual endorse-
ment of the entire framework, all comments and quer-
ies were carefully addressed by the CWG in subsequent
revisions. Authors made reasoned judgment where
contradictory views were expressed by panel members
on an issue [25-27]. For clarity and consistency the key
terminologies and definitions used in this report are
summarised in Table 1 (also Additional file 2).
Levels of intervention and required facilities for severe
jaundice
The average AGREE II-GRS ratings of the 21 guidelines
reviewed ranged from 41% for Ghana and 99% for UK’s
NICE (see Additional file 1: Table S1). Priority was given
to guidelines with high quality scores (≥70%) except for
issues pertinent to clinical practice in LMICs but not ex-
plicitly addressed by these guidelines such as factors ac-
counting for delays in seeking and receiving appropriate
care [17]. Only four guidelines (Ghana, India, Kenya and
WHO) were from eligible LMICs, and two (Ghana and
WHO) did not meet the 70% quality rating threshold.
The American Academy of Paediatrics (AAP) guideline
was the benchmark for the majority of high scoring na-
tional guidelines including NICE [4,5]. The interventions
and tools proposed for each level of health care delivery
are summarised in Table 2.
Table 1 Terminologies and definitions adopted in this paper
Terminology Definitions
Clinically significant
hyperbilirubinaemia
Significant hyperbilirubinaemia: any unconjugated bilirubin level requiring treatment with phototherapy which
varies with post-natal age and aetiology (typically TSB ≥12 mg/dL (205 μmol/L) in many LMICs).
Severe hyperbilirubinaemia: Bilirubin levels at/near exchange transfusion levels based on post-natal age and aeti-
ology (typically TSB ≥20 mg/dL or 342 μmol/L in many LMICs) and/or any elevated TSB associated with signs of
acute bilirubin encephalopathy.
Bilirubin encephalopathy: abnormal neurological signs and symptoms caused by bilirubin toxicity to the basal
ganglia and various brainstem nuclei.
Acute bilirubin encephalopathy (ABE): acute manifestations of bilirubin toxicity seen within fourteen days after
birth. Classic early signs include poor feeding, lethargy and tone abnormalities progressing to high-pitched cry, in-
creasing hypertonia - especially of extensor muscles, with retrocollis, opisthotonus and obtundation in association
with the kernicteric facies.
Kernicterus: Permanent or chronic neurologic damage, including choreo-athetoid cerebral palsy, enamel dysplasia,
paralysis of upward gaze, hearing impairments including auditory neuropathy spectrum disorders.
Low- and middle-income coun-
tries (LMICs)
The target population for this review consists of the 91 countries with per capita Gross National Income (GNI) of
≤ US$6,000 using the Human Development Report 2013 by the United Nations Development Program (UNDP)
as there is no single definition of “resource-poor countries” in the literature and developmental status varies
greatly among the approximately 140 countries classified as LMICs by the World Bank [17]. (see Additional file 2:
Table S2)
Levels of health care delivery Three levels of healthcare delivery were considered: primary, secondary and tertiary. Typically, the primary level
consists of community health centres and outposts managed by community health workers. Secondary/first-
level referral centres include district or general hospitals while the tertiary level consists of specialist or teaching
hospitals.
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The contribution of maternal/family knowledge gaps re-
garding the importance of neonatal jaundice commonly
manifesting in late presentation of infants with severe
hyperbilirubinaemia to health services in LMICs is well
documented [17]. Mothers and families are able to de-
tect jaundice from yellowish discolouration of the skin
in their newborns accurately, if appropriately educated
[4]. Educating pregnant women, especially primigravidae
during antenatal clinics, on the risks and adverse conse-
quences of severe hyperbilirubinaemia, avoidance of po-
tentially harmful traditional/herbal therapies and the
mis(use) of haemolytic agents should be a priority [17].
Routine determination of mother’s blood type and timely
provision of anti-D globulin should be widely promoted to
prevent Rh and neonatal jaundice due to other haemolytic
diseases [14,32]. Educational interactions with mothers
and families must also recognise and seek to address com-
mon barriers to appropriate health-seeking behaviour for
childhood illnesses [17]. Although most infants are born
outside hospitals in many LMICs, pre-discharge counsel-
ling of mothers who deliver in hospitals on the risks of
hyperbilirubinaemia after discharge should be considered.
Infants that are exclusively breastfed have an increased
risk for severe hyperbilirubinaemia in the first 2 to 5 days
of life compared to formula-fed infants [33]. It is there-
fore, essential to provide good lactation support to all
mothers at all levels of care to increase successful breast-
feeding, at least 8–12 times a day, as breast-milk benefits
outweigh the risk [4,5,33]. Mothers, families and their
jaundiced infants will also be best served by informationprovided during antenatal care, about hospitals in their
communities that are able to provide requisite support
for neonatal hyperbilirubinaemia [17].
Mothers who deliver at home, especially those who do
not attend antenatal clinics present a special challenge
that must be appropriately addressed in various commu-
nities. The inclusion of neonatal jaundice in the WHO
recommended training on essential newborn care for
traditional/home birth attendants, community and lay
health workers should be considered in such settings
[34-36]. The training should also be geared towards
avoidance of haemolytic agents or traditional therapies,
early recognition of the onset of jaundice by mothers
and care givers, and surveillance for timely presentation
to the nearest health facility [17].
Early detection, diagnosis and monitoring
Early identification of infants at risk of severe hyperbilir-
ubinaemia is an essential component of newborn care.
All newborns at all levels should be examined within
24 hours of birth and in the following two days. Mothers
and other care-givers should be encouraged to look for
jaundice by blanching the skin (on the nose in particular),
looking at the gums and examining the eyes [4]. The use
of Kramer’s chart (see Additional file 3: Figure S1) espe-
cially in primary care settings remains valuable despite its
limitation in correlating with the severity of jaundice
[37,38]. So also is blanching of the gums possibly with an
icterometer, particularly in dark-skinned babies [39].
Healthcare professionals and parents are capable of recog-
nizing jaundice, but not very good at assessing its severity
Table 2 Levels of intervention and suggested tools for managing neonatal hyperbilirubinaemia in low and
middle-income countries
Proposed tasks or tests [Applicable level of care]* Suggested tools and facilities
Primary prevention
• Education of existing and expectant mothers, families and health care providers on [P, S & T]: • Educational materials including posters and audio-
visual aids where available, pictures and/or video
clips of infant survivors of BIND and/or Kernicterus.
This material should include signs of both early and
late ABE/BIND and potential long-term
consequences of ABE/BIND for both the community
and the health care providers. [P, S & T]
o The transient physiologic course but with potential to increase to harmful levels and it's
variability from baby to baby
o The avoidance of haemolytic substances (including camphor/naphthalene balls,
menthol-containing powder, creams and balms, e.g. Wintergreen oil).
o The benefits of early detection accompanied by timely and appropriate treatment in health
facilities adequately-equipped for newborn care.
Access to laboratory appropriately resourced for
clinical investigations. [S & T]
o Discouraging traditional therapies as well as indiscriminate use of self-prescribed
medications e.g. ampicillin-cloxacillin.
o Recognition of acute bilirubin encephalopathy/Bilirubin-Induced Neurologic Dysfunction (BIND)
o The value of “clean birth” to prevent or minimize the risk of infection (sepsis)
• Referral to secondary or tertiary centers of all preterm babies (<35 weeks gestation) and
surveillance for full-term infants with history of medically-treated jaundice in a sibling
presenting at primary health centers. [P]
• Promotion and support for successful breastfeeding. [P, S & T]
• Screening of expectant mothers for the risk of blood group incompatibilities using routine ABO
& Rh with counseling on the importance of Rh immunoglobulin ensuring availability when
indicated. [P, S & T]
• Judicious use of oxytocin during labor. [S & T]
• Identification of babies with extensive bruises, cephalhaematomas and at risk for concealed
haematomas e.g. those from difficult deliveries. [P, S & T]
• Request blood test to rule out Glucose-6-phosphate dehydrogenase (G6PD) deficiency in
high-risk populations. [S & T]
• Early phototherapy for infants with hemolytic diseases. [S & T]
Early detection, diagnosis and monitoring
• Routine examination of all newborns within 24 hours of birth and the next 48 hours for
possible jaundice. [P, S & T]
• Well-lit examination room or nursery with natural
daylight (minimum). [P, S & T]
• If jaundice is suspected, examine infant naked in a well-lit room or, preferably in natural
daylight near a window guided by Kramer’s chart (Additional file 3: Figure S1). Recognize that
estimation of the degree of hyperbilirubinaemia based on visual signs of jaundice can lead to
errors, particularly in darkly pigmented infants. Blanching of the gum may be more reliable and
helpful in dark skinned babies. [P, S & T]
• Transcutaneous (TcB) Bilirubinometer e.g. JM103®
or Bilicheck® (minimum) or Icterometer. [P, S & T]
• Rapid micro device for total plasma/serum
bilirubin (TSB) (minimum). [S & T]
• Bilirubinometer for total serum & direct bilirubin
measurement (minimum). [S & T]
• If jaundice is visible, measure the total serum bilirubin (TSB) or transcutaneous bilirubin (TcB)
level. TcB values above 12 mg/dl (205 μmol/L) should be cross-checked where possible with
TSB measurement. [P, S & T]
• Access to laboratory facilities for: [S & T]
o Blood group, Rh, G6PD tests (minimum)
o Components of sepsis screen such as
Complete Blood Count, Blood/Urine/CSF
cultures, CRP and/or other rapid screening tests
• Establish if infant has early signs of acute bilirubin encephalopathy (ABE) or qualifies as high risk
including possible hemolytic diseases, hypothermia, hypoglycemia, or sepsis (see Algorithm in
Figure 1). [P, S & T]
o Metabolic screening e.g. hypothyroidism,
galactosaemia when indicated.
• Follow the Algorithm and Table 3 for actionable levels. [P, S & T]
• Ensure follow-up of infants discharged before 48 hours after delivery especially those with
established risk factors within 1–2 days of discharge (take advantage of BCG visit and any other
times infants <2 weeks are seen). [P, S & T]
Treatment
• Follow the Algorithm and Table 3 for actionable levels after country specific adaptations. [S & T] • Effective Phototherapy Units [S & T]
• When indicated (particularly, in the presence of isoimmune haemolytic diseases), ensure early
treatment of newborns with intensive phototherapy to minimize the need for exchange transfusion.
[S & T]
o Special Blue-light Phototherapy Unit (ideal)
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Table 2 Levels of intervention and suggested tools for managing neonatal hyperbilirubinaemia in low and
middle-income countries (Continued)
o Light emitting diodes (LED) Phototherapy
Unit (ideal)
• Ensure that the irradiance levels of phototherapy units are periodically monitored and the
recommended specifications strictly followed. [S & T]
o Fluorescent white or blue bulbs (minimum)• Be familiar with simple and inexpensive adjustments that can significantly improve the
effectiveness of phototherapy devices. [S & T]
• Irradiance Meters (spectro-radiometers) (ideal). [S & T]
• Access to blood bank with fresh (ideally less than 3 days old) whole blood for ET
appropriately compatible with mother and baby (O and Rh specific). [S & T]
• Maximize irradiance by placing the units as close
as possible without overheating the infants (usually
10–20 cm above the baby if using cool lights (unless
specified otherwise by manufacturer), using
reflecting materials on all sides of cots, exposing as
much of the baby as possible (thereby maximizing
spectral power [irradiance x size of irradiated area]);
and change florescent tubes according to
manufacturer’s recommendations if available or
periodically (8–12 weeks) if unable to measure
irradiance levels [S & T]
• Intravenous immunoglobulins (IVIG) may be useful when nearing ET but existing
evidence is not conclusive. [T]
• Laboratory facilities for albumin [S & T]
• Ensure that the eyes are covered but keep the cover small to maximize surface available for PT.
[P, S & T]
o Consider bilirubin-albumin ratio in addition to
but not in lieu of total bilirubin level as a
factor in determining the need for an
exchange transfusion.• Ensure that male genitals are covered (controversial) unless for infants nearing exchange
transfusion level. [P, S & T]
• Ensure that babies are placed in cots not incubators when under phototherapy unless they are
hypothermic. [S & T]
• Ensure that blood samples for relevant investigations are collected and refrigerated before initiating
exchange transfusion and any blood samples are protected from light including the PT light. [S & T]
• If available, consider the use of duly approved
filtered sunlight phototherapy (FS-PT) in tropical
settings with irregular electricity supply and lack of
adequate or functional conventional phototherapy
(CPT) units with careful and frequent monitoring of
infants for temperature fluctuations. [ P & S]
• Ensure that an infant with clinical signs of moderate-severe ABE receives exchange transfusion
promptly. Place the infant under the best phototherapy available while preparing for the
exchange transfusion.[S & T]
• Ensure that the infant remains adequately hydrated and is breastfeeding well/feeding well. [P, S & T]
• Avoid drugs that compete for albumin binding such as sulfonamides, ceftriaxone, and
acetylsalicylic acid. [S & T]
Follow-up evaluation
• Assessment of non-jaundiced infants on days 3 and 5. [P, S & T] • Tools for age-appropriate developmental
assessment. [S & T]
• Assessment of jaundiced infants regularly in the first 7–10 days or until jaundice is clearly
resolved. [P, S & T] • Automated Otoacoustic Emissions (AOAE). [S & T]
• Educate parents on the need for a follow-up neuro-developmental assessment of all infants
treated for severe hyperbilirubinaemia with intensive phototherapy or exchange transfusion or
with a history of such treatment at age 3–6 months. [P, S & T]
• Automated Auditory Brainstem Response (AABR).
[S & T]
• Access to diagnostic evaluation with Auditory
Brainstem Response (ABR) (ideal). [T]
• Ensure that, at the minimum, such developmental assessment includes auditory brainstem
response audiometry, language processing/language development and clinical evaluation of
abnormalities of tone, posture and movements for infants with signs of ABE/BIND, who had
exchange transfusion and those with a bilirubin level of >20 mg/dL. [S & T]
• Consider Magnetic Resonance Imaging (MRI) for
early detection of potential neurotoxicity if readily
available, can be done without sedation and does
not delay treatment. [T]
• Disseminate information on the local providers of age-appropriate developmental evaluation of
infants and young children to the affected parents on discharge or during any subsequent
clinical consultations. [S & T]
*Level of care where task/test should be available routinely: Primary/Community Health Center [P], Secondary/District Hospital [S], Tertiary/Children’s’ Hospital [T].
For a comprehensive list of essential infrastructural and human resources typically required for secondary/district hospitals see: UNICEF India. Toolkit for Setting up
of Special Care Units, Stabilization Units and Newborn Care Units. New Delhi: UNICEF India, 2009.
➢→ Conventional Phototherapy (CPT): Phototherapy in which intensity of blue light (400–520 nm) with a peak wavelength of 450 ± 20 nm not less than 8 μW/
cm2/nm is applied to the greatest possible surface area of the infant. The light sources are usually special blue fluorescent lamps, compact florescent lamps (CFL)
or halogen spotlights. If none of these are available, ordinary commercial white/daylight fluorescent lights should be considered, but brought as close as possible
(10-20 cm) to the baby without overheating.
➢→ Light-emitting diode Phototherapy (LED-PT): Phototherapy devices which emit most of their light in the 450–470 nm spectrum. This range corresponds to the
peak absorption wavelength (458 nm) at which bilirubin is broken down. Blue LEDs are power efficient, portable devices with low heat production so that they
can be placed very close to the skin of the infants without any apparent untoward effects.
➢→ Intensive Phototherapy (IPT): Phototherapy in which a high intensity of blue light (400–520 nm) ≥30 μW/cm2/nm is applied to the greatest possible surface
area of the infant. In usual clinical situations, this will require special high-intensity fluorescent tubes, or CPT lamps placed approximately 30 cm (10 cm for cool
blue light) above the infant, who can be nursed in a bassinet.
➢→ Filtered Sunlight Phototherapy (FS-PT): Treatment with specially filtered sunlight using custom pre-tested window-tinting films that protect against potentially
harmful ultra-violet and infra-red rays.
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more reliable and helpful in ruling out hyperbilirubinae-
mia than estimating bilirubin levels [4].
The suggested pathways of care for all babies, adapted
from NICE guidelines, are described in Figure 1 [4]. At a
minimum, infants with gestational age <38 weeks, from
high-risk racial groups, previous sibling(s) with a history
of treated jaundice, visible jaundice in the first 24 hours
of birth, family history of G6PD deficiency or blood
group incompatibilities, should be considered as high
risk and should be monitored for hyperbilirubinaemia at
all levels of care [4,5]. Ongoing training of health
workers on the signs and symptoms of ABE including
the use of a protocol for bilirubin-induced neurologic
dysfunction (BIND) is essential for facilitating timely re-
ferral and intervention (see Additional file 4: Table S3)
[40,41]. Subtle, moderate and occasionally even ad-
vanced BIND is likely reversible [42,43]. Timely detec-
tion and treatment of BIND as suggested by the AAP
and others is therefore, useful in forestalling the progres-
sion of this potentially devastating condition.
The objective tests for estimating and monitoring the
degree of jaundice are transcutaneous bilirubin (TcB)
and/or TSB. TcB is a non-invasive, portable screening
tool ideally used to determine the need for the more ac-
curate TSB which requires a venous or capillary blood
sample [44-47]. TcB values above 12 mg/dl (205 μmol/L)
should be checked where possible with TSB measure-
ment [47]. TcB becomes unreliable after commencement
of phototherapy unless measurements are taken from an
area of skin that has been shielded from phototherapy
with a photo-opaque patch [47]. However, currently
these devices, especially TSB, may not be readily afford-
able in many resource-limited settings. Low-cost and
minimally invasive point-of-care tools for plasma/serum
bilirubin measurements are currently being piloted and
hold promise for LMICs [48]. The interpretation of
TSB/TcB and the recommended actions are provided in
Table 3 [47-51]. Besides TSB estimation, access to la-
boratory facilities for real-time clinical investigations
should at a minimum include evaluation of blood group
incompatibilities and G6PD status [4,5].
For infants delivered in hospitals and discharged before
48 hours, follow up assessment within 1–2 days after dis-
charge with a TcB, or at a minimum, physical examination
should be considered. Table 3 may be used to assess the
risk of subsequent hyperbilirubinaemia at the time of dis-
charge. Infants who present in the first week of life should
be routinely examined for possible jaundice.
Treatment
Phototherapy and exchange transfusion are well-
established as the most effective treatments for severe
hyperbilirubinaemia [4,5]. The proposed actionable TSB/TcB levels for phototherapy and exchange transfusion
reflecting available evidence on current practices for the
care of jaundiced infants in LMICs are presented in
Table 3 [17,22,52]. We adopted the tabular format in the
Kenya 2013 guidelines (see Additional file 1: Table S1)
for ease of reference at all levels of care. These conserva-
tive bilirubin levels may be warranted in settings where
the incidence of severe hyperbilirubinaemia is high, late
presentation common, determination of haemolytic risk
(Blood type/Rh/G6PD) is not possible routinely at birth,
and quality of phototherapy is sub-optimal. Higher levels
for phototherapy and especially exchange transfusions at
or near those recommended by the AAP or NICE guide-
lines should be strongly considered in tertiary care settings
with facilities for intensive phototherapy. A centre or hos-
pital at any level that is not appropriately resourced to
provide the required treatment should promptly refer the
infant to the closest, appropriate health facility.
There are various phototherapy devices using different
light sources: fluorescent tubes, halogen lamps and light
emitting diodes (LED). An effective phototherapy device
should produce specific blue-light wavelengths (peak
emission: 450 ± 20 nm), preferably in a narrow band-
width to about 80% of an infant’s body surface area [18].
Conventional phototherapy (CPT) should have an irradi-
ance of at least 8-10 μW/cm2/nm and intensive photo-
therapy should have an irradiance of ≥30 μW/cm2/nm
(from either a single or multiple phototherapy units).
LED devices are as effective as other light sources in de-
creasing TSB but have special advantages in LMICs
[53,54]. They are more power efficient, portable, weigh
less, have a longer life span and lower heat production,
making them more suitable for intensive phototherapy
than fluorescent bulbs. Irradiance meters for monitoring
PT units should be readily available, as well as spare re-
placement bulbs.
Costs of providing intensive or special care for jaun-
diced newborns could be prohibitive, next only to that
of caring for preterm babies in LMICs [55]. However,
the development of affordable phototherapy devices and
using simple inexpensive enhancements such as hanging
white reflecting material around cots (being careful to
avoid overheating particularly from halogen lamps), chan-
ging bulbs regularly and reducing the distance between
baby and lamps, improve the effectiveness of phototherapy
[18,19,56,57]. WHO maintains a valuable compendium of
innovative and low-cost technologies including photother-
apy devices recommended for LMICs [58]. Whatever the
light-source, the effectiveness of phototherapy devices can
be compromised by erratic power supply, inadequate skin
exposure from overcrowding with multiple infants placed
under a single device, sub-optimal irradiance levels, and
poor device maintenance [18,19]. Failure to address these
issues is likely to increase the frequency of avoidable
Figure 1 Algorithm for the care of newborns with hyperbilirubinaemia in LMICs.
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therapy devices are properly monitored, regularly main-
tained, and staff well trained on how to care for infantsreceiving phototherapy. If enough effective phototherapy
devices are not available in very busy resource-constrained
settings, clinical judgement as to which infants should
Table 3 Suggested actionable treatment or referral TcB and/or TSB (mg/dL or μmol/L) levels in infants with
hyperbilirubinaemia
Age (in hours) Repeat TcB/TSB daily if
baby is not under PT
Begin CPT or Refer
at TcB/TSB
Begin IPT or Refer
at TcB/TSB
Frequency of Monitoring
TcB or TSB under PT
Consider ET at
TcB/TSB
0-12 any visible jaundice 2-3 (34–51) >3 (51)) 6 hrly 10-12 (171–205)
>12-24 ≥4 (68) 4-5 (68–86) >5 (86) 6 hrly 11-13 (188–222)
>24-36 ≥5 (86) 6-7 (103–120) >7 (120) 6 - 24 hrs 13-15 (222–257)
>36-48 ≥7 (120) 7-9 (120–154) >9 (154) 6 - 24 hrs 14-16 (239–274)
>48-60 ≥9 (154) 9-11 (154–188) >11 (188) 6 - 24 hrs 15-17 (257–291)
>60-72 ≥10 (171) 10-12 (171–205) >12 (205) 6 - 24 hrs 16-18 (274–308)
>72-84 ≥10.5 (180) 11-13 (188–222) >13 (222) 6 - 24 hrs 16-19 (274–325)
>84-96 ≥11 (188) 12-14 (205–239) >14 (239) 6 - 24 hrs 17-20 (291–342)
>96-108 ≥11.5 (197) 12-15 (205–257) >15 (257) 6 - 24 hrs 17-20 (291–351)
>108 ≥12 (205) 13-16 (222–274) >16 (274) 6 - 24 hrs 17-20 (291–351)
TcB (Transcutaneous bilirubinometry), TSB (Total serum bilirubin), PT (Phototherapy), CPT (Conventional PT) ≥10 μW/cm2/nm, IPT (Intensive PT) ≥30 μW/cm2/nm,
ET (Exchange transfusion).
AAP (American Academy of Pediatrics), LMICs (Low and middle-income countries), G6PD (Glucose-6-Phosphate Dehydrogenase).
Notes:
•→ The above levels are primarily adapted from the high/medium risk categories of AAP guidelines. Generally, levels of 2 mg/dL (34 μmol/L) below AAP
recommendations are proposed due to multiple confounding factors such as the high risk status of many infants in LMICs, the limited facilities for clinical
investigations, quality variability of phototherapy devices and the high incidence of ABE/kernicterus in many LMICs [e.g. see Guidelines #15 & 17 in Additional file
1: Table S1]. Phototherapy and especially exchange transfusion levels at or near those recommended by the AAP or NICE exchange guidelines should be strongly
considered in tertiary care settings with intensive phototherapy.
•→ These proposals may be adjusted as appropriate depending on the available facilities in each clinical setting and the risk profile of the infant with a view to
avoiding overtreatment or under-treatment.
•→ Factors that place infants at higher risk in many LMICs include but are not limited to widespread exclusive breastfeeding, G6PD deficiency, unrecognised
haemolysis such as blood group incompatibilities and sepsis/infection.[e.g. see Olusanya BO, Osibanjo FB, Slusher TM: Risk factors for severe hyperbilirubinaemia in
low and middle-income countries: a systematic review and meta-analysis. PLoS ONE 2015,10(2):e0117229.]
•→ The distinction between when to begin CPT versus IPT is important in LMICs due to the sub-optimal quality of phototherapy and the limited number of IPT
units in many settings. No such clear distinction exists in the AAP guidelines.
•→ If TcB level indicates PT, verify level using TSB measurement if available. It is acceptable to determine need for TSB with a TcB and it may be acceptable to
use TcB alone (under a photo-opaque patch) to follow infants under CPT. TcB values above 12 mg/dl (205 μmol/L) should be cross-checked where possible with
TSB measurement.
•→ All blood specimens for TSB measurement must be shielded from light to prevent photo-degradation of the sample serum bilirubin.
A centre or hospital, at any level, not appropriately resourced to provide the required treatment should refer promptly to the closest suitable health facility.
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Under such conditions, a BIND assessment can aid deci-
sions for intervention [40,59].
Guidelines for hyperbilirubinaemia in many high-
income countries prohibit exposure to sunlight as a form
of treatment [4,5,60]. This is primarily due to safety con-
cerns regarding potentially harmful infrared and ultra-
violet rays and possible sunburn. In Ghana, exposure of
jaundiced infants to sunlight is acknowledged as a treat-
ment option [61], but WHO guidelines and some other
developing countries like Malaysia, India and Kenya dis-
courage or have not made provisions for sunlight ther-
apy (see Additional file 1: Table S1). However, mothers
and caregivers with or without the support of health
workers continue to expose their jaundiced babies to
direct sunlight even in high-income countries [62-66].
Emerging evidence suggests that the potential risks can
be mitigated through specially filtered film canopies
which have been successfully piloted in West Africa
[67,68]. However, their use is still experimental and lim-
ited to daytime care at periods with favourable climatic
conditions. In remote tropical locations where access toconventional treatment is not assured, the trade-off be-
tween the risk of ABE/kernicterus and of exposure to
sunlight remains a challenge that requires individual and
informed judgment call in the patient’s best interest.
Immediate exchange transfusion is warranted when
phototherapy has failed to effectively curtail the rate of
bilirubin rise and the TSB/TcB measurement is near ex-
change levels or the infant has any of the signs of mod-
erate to advanced ABE regardless of the TSB/TcB levels
(Figure 1, Table 3). This treatment is most likely to be
available at tertiary hospitals with trained personnel
and facilities for special care, including monitoring and
resuscitation capabilities. As exchange transfusion is
not without risks [69-71], its frequency should be mini-
mised as far as practicable. Exchange transfusion with
G6PD deficient donor blood should be avoided where
possible as this may prolong time under phototherapy
and result in repeat exchange transfusions [72]. Simi-
larly, blood should be screened for HIV and hepatitis.
Rh-negative blood should be used for neonates with
Rh-isoimmunisation while O group should be used for
neonates with ABO incompatibility.
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D-penicillamine, phenobarbital, metalloporphyrins, clofi-
brate, bile salts, laxatives and bilirubin oxidase are in-
conclusive and these interventions have not been
recommended [73]. Likewise traditional herbs or medi-
cations used to treat newborn jaundice in many home
settings are not recommended.
Follow-up evaluation
The manifestations of BIND such as cerebral palsy,
auditory impairments, epilepsy, gross motor deficits,
behavioural problems and intellectual difficulties are
not uncommon in LMICs [9-13]. Follow-up evaluation
of survivors of severe hyperbilirubinaemia for potential
neurodevelopmental sequelae is necessary to facilitate
early detection and intervention for the affected infants.
This must be considered as an integral part of any clin-
ical protocol for the management of infants who have
been treated for severe hyperbilirubinaemia. Because
hearing impairment, including auditory neuropathy
spectrum disorders in the first year of life is often not
clinically apparent, at-risk infants must be objectively
evaluated within the first three months and monitored
for language development in the first two years of life
irrespective of the hearing test result. Referral to the
audiology or otolaryngology unit of a tertiary hospital
should therefore be considered. Several low-cost and
simple-to-use validated tools for early developmental
assessment as well as approaches to effective interven-
tion in resource-limited settings have also been docu-
mented [74,75].
Limitations
While we set out to ensure that our recommendations
are realistic and consistent with the prevailing condi-
tions in most LMICs, the methodological approach
used in this document deserves clarification. We
followed standard protocols for guideline adaptation in-
cluding a comprehensive review of the priority issues to
be considered, the formation of a working group, qual-
ity rating of existing guidelines and independent review
by a panel of leading clinicians and experts on newborn
care from different world regions [25-27]. However, we
did not grade specific studies in support of various pro-
posals in this paper, more so because the body of evi-
dence was predominantly adapted from existing
guidelines or supported by the best available data from
LMICs [17,22,76]. Neonatal hyperbilirubinaemia is fre-
quently underpinned by complex interactions of diverse
biological and environmental risk factors across popu-
lations. It is our view therefore, that each LMIC still
needs to develop context-specific guidelines for their
own population [77]. Such an initiative should be
broadened to involve key stakeholders including parentgroups and community leaders. It may be helpful to
prepare separate documents for each level of care to
avoid information overload especially at the primary
care level. While the scope of this framework is not ex-
haustive, like any of the existing guidelines, we believe
that most of the recommendations will still be valuable
to LMICs that did not meet our selection criteria. Fi-
nally, strong clinical and public health leadership at all
levels will be required to surmount the challenges that
typically mitigate against initiatives for improved child
and newborn care in LMICs [78,79].Conclusions
In sharp contrast to the practice in most high-income
nations, national guidelines for the effective manage-
ment of severe hyperbilirubinaemia are rare in LMICs
where the disease burden is greatest. In this paper, the
authors have attempted to identify a number of key
considerations for the effective management of hyper-
bilirubinaemia in LMICs that can be considered truly
resource-poor, based on their HDI status. Most of the
recommendations have been adapted from existing evi-
dence or consensus-based guidelines in the industria-
lised world after extensive consultations at different
stages with experts from various countries. Efforts were
made to ensure that the proposed framework is consist-
ent with universally accepted requirements for quality
in healthcare. It is hoped that these recommendations
will assist in the development of context-specific na-
tional guidelines and mobilisation of requisite resources
for the care of infants with or at risk of severe hyperbi-
lirubinaemia at all levels of healthcare delivery in
LMICs.Additional files
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